Regenerative Stem Cell Therapy for Stroke in Europe 1-RESSTORE1

Summary

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke recovery and patients quality of life.

Timeline

Start

2018-06-02

Primary completion

2025-07-01

Completion

2027-07-01

Publications

• Legris L, Moisan A, Jaillard A, Bonnet L, Moulin T, Sibon I, Touze E, Favre-Wiki I, Cordonnier C, Dellaschiava L, Mazighi M, Rosso C, Alamowitch S, Calvet D, Barbieux-Guillot M, Roux S, Mojallal AA, Boucher F, Thuriot A, Soulard J, Naegele B, Perennou D, Roustit M, Putkaradze Z, Hommel M, Lehmann A, Colombat J, Chorfa F, Maucort-Boulch D, Lamalle L, Grand S, Krainik A, Detante O. Regenerative stem cell therapy for stroke in Europe (RESSTORE): a multicenter randomized controlled efficacy clinical trial. Front Stroke. 2024 Sep 27;3:1416490. doi: 10.3389/fstro.2024.1416490. eCollection 2024.

Drugs

Indications